Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 14/20 | 0.50 |
| ▸ | FABP4 | P15090 | 5/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392622 | 0.98 | PLA2G2A (0.50) | PLA2G2AFABP4MTNR1AMTNR1B | |
| SCHEMBL6397021 | 0.90 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 | |
| SCHEMBL6397436 | 0.88 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 | |
| SCHEMBL5771305 | 0.82 | PLA2G2A (0.67) | PLA2G2AFABP4 | |
| SCHEMBL5770083 | 0.81 | PLA2G2A (0.67) | PLA2G2A | |
| SCHEMBL5769684 | 0.80 | PLA2G2A (0.64) | PLA2G2A | |
| SCHEMBL5766359 | 0.79 | PLA2G2A (0.64) | PLA2G2A | |
| SCHEMBL6393255 | 0.77 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 | |
| SCHEMBL5770181 | 0.76 | FABP4 (0.48) | PLA2G2AFABP4FABP3 | |
| SCHEMBL6404040 | 0.75 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872743-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040063941-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063941-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | PLA2G2A 26/4885FABP4 210/4885FABP3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.